

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	NA

Vyvanse (lisdexamfetamine dimesylate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Vyvanse (lisdexamfetamine dimesylate)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Vyvanse (lisdexamfetamine dimesylate) may be approved if the following criteria is met:

- I. Individual is 6 years of age or older; **AND**
- II. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD);
AND
- III. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and insufficient response or intolerance to **one** of the following:
 - A. Methylphenidate extended-release;
 - OR**
 - B. Extended-release amphetamine/dextroamphetamine salt combination; **OR**
- IV. Individual has been diagnosed with coexisting ADHD and substance use disorder;

OR

- V. Individual is 18 years of age or older; **AND**
- VI. Individual has a diagnosis of moderate to severe binge-eating disorder.

Requests for Vyvanse (lisdexamfetamine dimesylate) may not be approved for the following:

- I. Individual is using as an agent for weight loss; **OR**
- II. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, or other serious heart problems; **OR**
- III. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	NA

Note:

Attention deficit hyperactivity disorder (ADHD) may also be referred to as attention deficit disorder (ADD).

Vyvanse (lisdexamfetamine) has black box warnings for abuse and dependence. CNS stimulants have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 26, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011; 128:1007-1022. Available from: <http://pediatrics.aappublications.org/content/128/5/1007.full.pdf>. Accessed: June 26, 2019.
6. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020.) AHRQ Publication No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011. Last Review July 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed: June 26, 2019.
7. Post RE and Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2012; 85(9):890-896. Available from: <http://www.aafp.org/afp/2012/0501/p890.html>. Accessed June 26, 2019.
8. Berkman ND, Brownley KA, Peat CM, et al. Management and Outcomes of Binge-Eating Disorder [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Dec. (Comparative Effectiveness Reviews, No. 160.) Table 1, DSM-IV and DSM-5 diagnostic criteria for binge-eating disorder. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK338301/table/introduction.t1/>. Accessed April 17, 2020.
9. Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. *Ann Intern Med*. 2016; 165: 409-20. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637727/pdf/nihms891228.pdf>. Accessed April 17, 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.